Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Medtronic
Mallinckrodt
Harvard Business School
AstraZeneca

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,207,191

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,207,191 protect, and when does it expire?

Patent 8,207,191 protects ALTABAX and is included in one NDA.

This patent has thirteen patent family members in six countries.

Summary for Patent: 8,207,191
Title:Process, salts, composition and use
Abstract: The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy.
Inventor(s): Forth; Michael Anthony (Tonbridge, GB), Kopelman; Susan ShuMei Hu (King of Prussia, PA), Muller; Francis Xavier (King of Prussia, PA), Sanderson; Francis Dominic (Harlow, GB)
Assignee: Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:12/977,127
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition;

Drugs Protected by US Patent 8,207,191

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Almirall ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes   Start Trial   Start Trial TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,207,191

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 450535   Start Trial
Germany 602004024417   Start Trial
European Patent Office 1663220   Start Trial
European Patent Office 2181995   Start Trial
Spain 2335284   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Baxter
McKesson
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.